Nisa Investment Advisors LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Nisa Investment Advisors LLC boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 10.9% in the first quarter, Holdings Channel reports. The institutional investor owned 2,977 shares of the company’s stock after purchasing an additional 293 shares during the period. Nisa Investment Advisors LLC’s holdings in Vaxcyte were worth $112,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PCVX. Brown Advisory Inc. grew its stake in shares of Vaxcyte by 2.5% in the first quarter. Brown Advisory Inc. now owns 570,258 shares of the company’s stock worth $21,533,000 after acquiring an additional 14,049 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Vaxcyte by 75.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 96,600 shares of the company’s stock worth $3,648,000 after purchasing an additional 41,517 shares in the last quarter. GF Fund Management CO. LTD. boosted its stake in Vaxcyte by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,192 shares of the company’s stock worth $121,000 after purchasing an additional 575 shares in the last quarter. Principal Financial Group Inc. grew its position in Vaxcyte by 52.0% during the 1st quarter. Principal Financial Group Inc. now owns 469,561 shares of the company’s stock valued at $17,731,000 after purchasing an additional 160,622 shares during the last quarter. Finally, J.Safra Asset Management Corp increased its stake in Vaxcyte by 65.8% during the 1st quarter. J.Safra Asset Management Corp now owns 3,161 shares of the company’s stock valued at $119,000 after purchasing an additional 1,254 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on PCVX shares. The Goldman Sachs Group dropped their target price on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a “strong-buy” rating in a research report on Monday, March 31st. Cantor Fitzgerald assumed coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an “overweight” rating on the stock. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Finally, Bank of America lowered their price target on Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Trading Down 3.1%

NASDAQ:PCVX opened at $36.21 on Friday. The company has a market cap of $4.67 billion, a PE ratio of -9.08 and a beta of 1.19. The company has a 50 day simple moving average of $33.84 and a two-hundred day simple moving average of $53.84. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). During the same period in the previous year, the firm posted ($0.85) earnings per share. Research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.